| ID | Type | Description | Link |
|---|---|---|---|
| N01-DK-9-2328 | Other Grant/Funding Number | NIH NIDDK Contract | |
| N01-DK-9-2323 | Other Grant/Funding Number | NIH NIDDK Contract | |
| N01-DK-9-2324 | Other Grant/Funding Number | NIH NIDDK Contract | |
| N01-DK-9-2325 | Other Grant/Funding Number | NIH NIDDK Contract | |
| N01-DK-9-2326 | Other Grant/Funding Number | NIH NIDDK Contract | |
| N01-DK-9-2321 | Other Grant/Funding Number | NIH NIDDK Contract | |
| N01-DK-9-2327 | Other Grant/Funding Number | NIH NIDDK Contract | |
| N01-DK-9-2319 | Other Grant/Funding Number | NIH NIDDK Contract | |
| N01-DK-9-2318 | Other Grant/Funding Number | NIH NIDDK Contract | |
| N01-DK-9-2320 | Other Grant/Funding Number | NIH NIDDK Contract | |
| N01-DK-9-2322 | Other Grant/Funding Number | NIH NIDDK Contract |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | NIH |
| National Institute on Minority Health and Health Disparities (NIMHD) | NIH |
| National Cancer Institute (NCI) | NIH |
Not provided
Not provided
Not provided
Not provided
The HALT-C Trial is a National Institute of Diabetes and Digestive and Kidney Diseases sponsored, randomized clinical trial of long-term use of Peginterferon alfa-2a (pegylated interferon) in patients who failed to respond to prior interferon treatment. All patients who enter the trial will be treated for 6 months with Peginterferon alfa-2a and Ribavirin. Patients who respond to this 6 month treatment will continue to be treated for an additional 6 months.
Patients who do not respond to this treatment will be eligible for the long-term maintenance phase of this study where patients will be randomly selected to be treated with Peginterferon alfa-2a or to discontinue treatment for 3.5 years. Patients in both arms of this study will be followed closely with quarterly study visits.
The combination of peginterferon plus ribavirin has recently been approved by the FDA for treatment of chronic hepatitis C. Patients who remain HCV-RNA positive after being treated for at least 6 months with peginterferon and ribavirin outside of this study may be eligible to directly enter the randomized portion of the HALT-C Trial.
The HALT-C study is designed to determine if continuing interferon long-term over several years will suppress Hepatitis C virus, prevent progression to cirrhosis, prevent liver cancer and reduce the need for liver transplantation.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| 1 | Experimental | Peg-interferon alfa-2a 90 mcg/week |
|
| 2 | Active Comparator | Standard of care followup |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Peginterferon alfa-2a + Ribavirin | Drug | Peginterferon alfa-2a 180 mcg/week injection, for 24 weeks, plus 1000-1200 mg Ribavirin oral (prescribed according to weight <75 kg, >75 kg) daily in two divided doses for 24 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Progression of Liver Disease as Indicated by Death, Hepatic Decompensation, Hepatocellular Carcinoma, or for Patients With Noncirrhotic Fibrosis at Baseline, an Increase in the Ishak Hepatic Fibrosis Score of 2 or More Points | Progression of liver disease within 1400 days as indicated by death, hepatic decompensation (variceal hemorrhage; ascites; spontaneous bacterial peritonitis; hepatic encephalopathy), hepatocellular carcinoma, a Child-Turcotte-Pugh (CTP) score of 7 or more on two consecutive study visits (score range 5-15, higher score indicates greater decompensation), or for patients with noncirrhotic fibrosis at baseline, an increase in Ishak hepatic fibrosis score (range 0-6, higher score indicates greater fibrosis) of at least 2 points by assessment of a liver-biopsy specimen obtained during the study | 1400 days (3.85 years) post randomization |
| Increase in Ishak Fibrosis Score by 2 Points or More at 2 or 4 Year Biopsies | For patients with noncirrhotic fibrosis at baseline, an increase in Ishak hepatic fibrosis score (range 0-6, higher score indicates greater fibrosis) of at least 2 points by assessment of a liver-biopsy specimen obtained during the study (collected at Year 2 and Year 4 biopsies, 1.5 and 3.5 years after randomization) | 1400 days (3.85 years) post randomization |
| Death From Any Cause | 1400 days (3.85 years) post randomization | |
| Development of Hepatocellular Carcinoma (HCC) | A diagnosis of development of hepatocellular carcinoma (HCC) was based on either
| 1400 days (3.85 years) post randomization |
| Child-Turcotte-Pugh (CTP) Score of 7 or Higher at Two Consecutive Study Visits | Child-Turcotte-Pugh (CTP) score of 7 or more on two consecutive study visits (score range 5-15, higher score indicates greater hepatic decompensation) |
| Measure | Description | Time Frame |
|---|---|---|
| Serious Adverse Events | A serious adverse event (SAE) is an untoward medical occurrence that results in any of the following:
Trial outcomes (except death) were not considered serious adverse events. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Gregory T. Everson, M.D. | UCHSC (University of Colorado) | Principal Investigator |
| Adrian M. Di Bisceglie, M.D. | St. Louis University | Principal Investigator |
| William M. Lee, M.D. | University of Texas, Southwestern Medical Center at Dallas | Principal Investigator |
| Marc Ghany, M.D. | LDS, NIDDK, NIH | Principal Investigator |
| Jules L. Dienstag, M.D. | Massachusetts General Hospital | Principal Investigator |
| Mitchell Shiffman, M.D. | Medical College of Virginia | Principal Investigator |
| Anna Lok, M.D. | University of Michigan | Principal Investigator |
| Tim Morgan, M.D. | University of California-Irvine/VA Medical Center-Long Beach | Principal Investigator |
| Karen Lindsay, M.D., M.M.M. | USC School of Medicine | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of California-Irvine/VA Medical Center-Long Beach | Long Beach | California | 90822 | United States | ||
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 15465617 | Background | Lee WM, Dienstag JL, Lindsay KL, Lok AS, Bonkovsky HL, Shiffman ML, Everson GT, Di Bisceglie AM, Morgan TR, Ghany MG, Morishima C, Wright EC, Everhart JE; HALT-C Trial Group. Evolution of the HALT-C Trial: pegylated interferon as maintenance therapy for chronic hepatitis C in previous interferon nonresponders. Control Clin Trials. 2004 Oct;25(5):472-92. doi: 10.1016/j.cct.2004.08.003. | |
| 19052125 |
Not provided
Not provided
Data are available at the NIDDK Central Repository: https://repository.niddk.nih.gov/studies/halt-c/?query=HALT-C
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Title | Description |
|---|---|---|
| FG000 | Peginterferon Alfa-2a 90 mcg/Week | Treatment with Peginterferon alfa-2a 90 mcg administered once weekly for an additional 42 months |
| FG001 | Standard of Care Followup | Stop any peginterferon alfa-2a/ribavirin therapy and followed prospectively for an additional 42 months without treatment |
| Title | Milestones | Reasons Not Completed | |||||
|---|---|---|---|---|---|---|---|
| Overall Study |
|
Not provided
Not provided
Not provided
| Hoffmann-La Roche |
| INDUSTRY |
Not provided
Not provided
Not provided
Not provided
Not provided
|
| Peginterferon alfa-2a | Drug | 90 mcg/week injection, for 3.5 years |
|
|
| 1400 days (3.85 years) post randomization |
| Variceal Hemorrhage | A gastrointestinal hemorrhage which is believed by the investigator to be due to bleeding esophageal or gastric varices. In general, an endoscopy will have been performed and will have revealed either direct evidence of variceal bleeding (bleeding varix, red wale sign) or historical evidence for significant upper gastro-intestinal bleeding plus upper endoscopy revealing moderate varices and no other site of bleeding is identified | 1400 days (3.85 years) post randomization |
| Ascites | Any abdominal fluid which is:
| 1400 days (3.85 years) post randomization |
| Spontaneous Bacterial Peritonitis | Any episode of spontaneous ascitic infection diagnosed on the basis of elevated neutrophil count (> 250/ml) in paracentesis fluid or positive bacterial cultures and clinical diagnosis in the absence of white blood cell (WBC) availability. | 1400 days (3.85 years) post randomization |
| Hepatic Encephalopathy | Any mental status alteration which is deemed by the investigator to be due to portosystemic encephalopathy, whether occurring during a provoked episode (GI bleeding, diuretics, usual sedative doses), or spontaneously (without apparent cause). | 1400 days (3.85 years) post randomization |
| 1400 days (3.85 years) post randomization |
| Changes in Fibrosis From Baseline at Year 2 or Year 4 Biopsy. | Change in Ishak hepatic fibrosis score (range 0-6, higher score indicates greater fibrosis) by assessment of a liver-biopsy specimen obtained during the study (collected at baseline, Year 2 and Year 4 biopsies, 1.5 and 3.5 years after randomization) | 1400 days (3.85 years) post randomization |
| Presumed Hepatocellular Carcinoma (HCC) | Presumed HCC was considered when histology was not available and alpha-fetoprotein (AFP) is <1000 ng/ml, if:
| 1400 days (3.85 years) post randomization |
| SF-36 Vitality Summary Score | Change from baseline to years 0.5, 1.5, 2.5, and 3.5 in Short Form Health Survey (SF-36) Vitality summary score. The SF-36 Vitality summary score is the sum of 4 individual scores. It is scaled from 0 to 100 with a score of 0 equivalent to maximum disability and a score of 100 equivalent to no disability. A negative value indicates a decrease in quality of life from baseline. | 0.5, 1.5, 2.5, and 3.5 years after randomization |
| SF-36 Physical Function Summary Score | Change from baseline to years 0.5, 1.5, 2.5, and 3.5 in Short Form Health Survey (SF-36) Physical Function summary score. The SF-36 Physical Function summary score is the sum of 10 individual scores. It is scaled from 0 to 100 with a score of 0 equivalent to maximum disability and a score of 100 equivalent to no disability. A negative value indicates a decrease in quality of life from baseline. | 0.5, 1.5, 2.5, and 3.5 years after randomization |
| SF-36 Mental Health Summary Score | Change from baseline to years 0.5, 1.5, 2.5, and 3.5 in Short Form Health Survey (SF-36) Mental Health summary score. The SF-36 Mental Health summary score is the sum of 5 individual scores. It is scaled from 0 to 100 with a score of 0 equivalent to maximum disability and a score of 100 equivalent to no disability. A negative value indicates a decrease in quality of life from baseline. | 0.5, 1.5, 2.5, and 3.5 years after randomization |
| Gyongyi Szabo, M.D., Ph.D. | UMass Medical School | Principal Investigator |
| USC School of Medicine |
| Los Angeles |
| California |
| 90033 |
| United States |
| UCHSC (University of Colorado) | Denver | Colorado | 80262 | United States |
| University of Connecticut Health Center | Farmington | Connecticut | 06030 | United States |
| Lds, Niddk, Nih | Bethesda | Maryland | 20892-1800 | United States |
| Massachusetts General Hospital | Boston | Massachusetts | 02114 | United States |
| UMass Memorial HealthCare, University Campus | Worcester | Massachusetts | 01655 | United States |
| University of Michigan | Ann Arbor | Michigan | 48109 | United States |
| Saint Louis University | St Louis | Missouri | 63104 | United States |
| University of Texas Southwestern - Dallas | Dallas | Texas | 75390-9195 | United States |
| Medical College of Virginia | Richmond | Virginia | 23298-0341 | United States |
| Result |
| Di Bisceglie AM, Shiffman ML, Everson GT, Lindsay KL, Everhart JE, Wright EC, Lee WM, Lok AS, Bonkovsky HL, Morgan TR, Ghany MG, Morishima C, Snow KK, Dienstag JL; HALT-C Trial Investigators. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon. N Engl J Med. 2008 Dec 4;359(23):2429-41. doi: 10.1056/NEJMoa0707615. |
| 41675321 | Derived | Imperial JC, McRae MP, Everson GT. When should I repeat the endoscopy in my patient with compensated cirrhosis, whom I just scoped and who had no or small varices? Transl Gastroenterol Hepatol. 2026 Jan 22;11:22. doi: 10.21037/tgh-25-133. eCollection 2026. |
| 37098004 | Derived | Yu L, Paski SC, Dodge J, Bambha K, Biggins SW, Ioannou GN. Effect of dietary branched chain amino acids on liver related mortality: Results from a large cohort of North American patients with advanced HCV infection. PLoS One. 2023 Apr 25;18(4):e0284739. doi: 10.1371/journal.pone.0284739. eCollection 2023. |
| 25079603 | Derived | Donlin MJ, Lomonosova E, Kiss A, Cheng X, Cao F, Curto TM, Di Bisceglie A, Tavis JE. HCV genome-wide genetic analyses in context of disease progression and hepatocellular carcinoma. PLoS One. 2014 Jul 31;9(7):e103748. doi: 10.1371/journal.pone.0103748. eCollection 2014. |
| 24886378 | Derived | Snow KK, Bell MC, Stoddard AM, Curto TM, Wright EC, Dienstag JL. Processes to manage analyses and publications in a phase III multicenter randomized clinical trial. Trials. 2014 May 7;15:159. doi: 10.1186/1745-6215-15-159. |
| 22688849 | Derived | Morishima C, Shiffman ML, Dienstag JL, Lindsay KL, Szabo G, Everson GT, Lok AS, Di Bisceglie AM, Ghany MG, Naishadham D, Morgan TR, Wright EC; HALT-C Trial Group. Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C. Am J Gastroenterol. 2012 Sep;107(9):1388-98. doi: 10.1038/ajg.2012.137. Epub 2012 Jun 12. |
| 22571902 | Derived | Morishima C, Di Bisceglie AM, Rothman AL, Bonkovsky HL, Lindsay KL, Lee WM, Koziel MJ, Fontana RJ, Kim HY, Wright EC; HALT-C Trial Group. Antigen-specific T lymphocyte proliferation decreases over time in advanced chronic hepatitis C. J Viral Hepat. 2012 Jun;19(6):404-13. doi: 10.1111/j.1365-2893.2011.01562.x. Epub 2011 Dec 16. |
| 22103814 | Derived | Fontana RJ, Litman HJ, Dienstag JL, Bonkovsky HL, Su G, Sterling RK, Lok AS; HALT-C Trial Group. YKL-40 genetic polymorphisms and the risk of liver disease progression in patients with advanced fibrosis due to chronic hepatitis C. Liver Int. 2012 Apr;32(4):665-74. doi: 10.1111/j.1478-3231.2011.02686.x. Epub 2011 Nov 22. |
| 22030902 | Derived | Everson GT, Shiffman ML, Hoefs JC, Morgan TR, Sterling RK, Wagner DA, Lauriski S, Curto TM, Stoddard A, Wright EC; HALT-C Trial Group. Quantitative liver function tests improve the prediction of clinical outcomes in chronic hepatitis C: results from the Hepatitis C Antiviral Long-term Treatment Against Cirrhosis Trial. Hepatology. 2012 Apr;55(4):1019-29. doi: 10.1002/hep.24752. Epub 2012 Mar 1. |
| 21931376 | Derived | Sterling RK, Wright EC, Morgan TR, Seeff LB, Hoefs JC, Di Bisceglie AM, Dienstag JL, Lok AS. Frequency of elevated hepatocellular carcinoma (HCC) biomarkers in patients with advanced hepatitis C. Am J Gastroenterol. 2012 Jan;107(1):64-74. doi: 10.1038/ajg.2011.312. Epub 2011 Sep 20. |
| 21829595 | Derived | O'Bryan JM, Potts JA, Bonkovsky HL, Mathew A, Rothman AL; HALT-C Trial Group. Extended interferon-alpha therapy accelerates telomere length loss in human peripheral blood T lymphocytes. PLoS One. 2011;6(8):e20922. doi: 10.1371/journal.pone.0020922. Epub 2011 Aug 4. |
| 21782771 | Derived | Rakoski MO, Brown MB, Fontana RJ, Bonkovsky HL, Brunt EM, Goodman ZD, Lok AS, Omary MB; HALT-C Trial Group. Mallory-Denk bodies are associated with outcomes and histologic features in patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2011 Oct;9(10):902-909.e1. doi: 10.1016/j.cgh.2011.07.006. Epub 2011 Jul 23. |
| 21760886 | Derived | O'Brien TR, Everhart JE, Morgan TR, Lok AS, Chung RT, Shao Y, Shiffman ML, Dotrang M, Sninsky JJ, Bonkovsky HL, Pfeiffer RM; HALT-C Trial Group. An IL28B genotype-based clinical prediction model for treatment of chronic hepatitis C. PLoS One. 2011;6(7):e20904. doi: 10.1371/journal.pone.0020904. Epub 2011 Jul 8. |
| 21699796 | Derived | Hoefs JC, Shiffman ML, Goodman ZD, Kleiner DE, Dienstag JL, Stoddard AM; HALT-C Trial Group. Rate of progression of hepatic fibrosis in patients with chronic hepatitis C: results from the HALT-C Trial. Gastroenterology. 2011 Sep;141(3):900-908.e1-2. doi: 10.1053/j.gastro.2011.06.007. Epub 2011 Jun 12. |
| 21520194 | Derived | Dienstag JL, Ghany MG, Morgan TR, Di Bisceglie AM, Bonkovsky HL, Kim HY, Seeff LB, Szabo G, Wright EC, Sterling RK, Everson GT, Lindsay KL, Lee WM, Lok AS, Morishima C, Stoddard AM, Everhart JE; HALT-C Trial Group. A prospective study of the rate of progression in compensated, histologically advanced chronic hepatitis C. Hepatology. 2011 Aug;54(2):396-405. doi: 10.1002/hep.24370. Epub 2011 Jun 23. |
| 21376050 | Derived | Freedman ND, Curto TM, Lindsay KL, Wright EC, Sinha R, Everhart JE; HALT-C TRIAL GROUP. Coffee consumption is associated with response to peginterferon and ribavirin therapy in patients with chronic hepatitis C. Gastroenterology. 2011 Jun;140(7):1961-9. doi: 10.1053/j.gastro.2011.02.061. Epub 2011 Mar 2. |
| 21374690 | Derived | Lok AS, Everhart JE, Di Bisceglie AM, Kim HY, Hussain M, Morgan TR; HALT-C Trial Group. Occult and previous hepatitis B virus infection are not associated with hepatocellular carcinoma in United States patients with chronic hepatitis C. Hepatology. 2011 Aug;54(2):434-42. doi: 10.1002/hep.24257. |
| 21335007 | Derived | Lambrecht RW, Sterling RK, Naishadham D, Stoddard AM, Rogers T, Morishima C, Morgan TR, Bonkovsky HL; HALT-C Trial Group. Iron levels in hepatocytes and portal tract cells predict progression and outcomes of patients with advanced chronic hepatitis C. Gastroenterology. 2011 May;140(5):1490-500.e3. doi: 10.1053/j.gastro.2011.01.053. Epub 2011 Feb 15. |
| 21139575 | Derived | Fontana RJ, Sanyal AJ, Ghany MG, Bonkovsky HL, Morgan TR, Litman HJ, Reid AE, Lee WM, Naishadham D; HALT-C Trial Study Group. Development and progression of portal hypertensive gastropathy in patients with chronic hepatitis C. Am J Gastroenterol. 2011 May;106(5):884-93. doi: 10.1038/ajg.2010.456. Epub 2010 Dec 7. |
| 21129375 | Derived | Lok AS, Everhart JE, Wright EC, Di Bisceglie AM, Kim HY, Sterling RK, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Morgan TR; HALT-C Trial Group. Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C. Gastroenterology. 2011 Mar;140(3):840-9; quiz e12. doi: 10.1053/j.gastro.2010.11.050. Epub 2010 Dec 1. |
| 21083592 | Derived | Freedman ND, Curto TM, Morishima C, Seeff LB, Goodman ZD, Wright EC, Sinha R, Everhart JE; HALT-C Trial Group. Silymarin use and liver disease progression in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis trial. Aliment Pharmacol Ther. 2011 Jan;33(1):127-37. doi: 10.1111/j.1365-2036.2010.04503.x. Epub 2010 Nov 2. |
| 20889211 | Derived | Kronfol Z, Litman HJ, Back-Madruga C, Bieliauskas LA, Lindsay KL, Lok AS, Fontana RJ; HALT-C Trial Group. No increase in depression with low-dose maintenance peginterferon in prior non-responders with chronic hepatitis C. J Affect Disord. 2011 Mar;129(1-3):205-12. doi: 10.1016/j.jad.2010.09.010. |
| 20675691 | Derived | Fontana RJ, Dienstag JL, Bonkovsky HL, Sterling RK, Naishadham D, Goodman ZD, Lok AS, Wright EC, Su GL; HALT-C Trial Group. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C. Gut. 2010 Oct;59(10):1401-9. doi: 10.1136/gut.2010.207423. Epub 2010 Jul 30. |
| 20564351 | Derived | Morgan TR, Ghany MG, Kim HY, Snow KK, Shiffman ML, De Santo JL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Dienstag JL, Morishima C, Lindsay KL, Lok AS; HALT-C Trial Group. Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology. 2010 Sep;52(3):833-44. doi: 10.1002/hep.23744. |
| 20362695 | Derived | Seeff LB, Everson GT, Morgan TR, Curto TM, Lee WM, Ghany MG, Shiffman ML, Fontana RJ, Di Bisceglie AM, Bonkovsky HL, Dienstag JL; HALT-C Trial Group. Complication rate of percutaneous liver biopsies among persons with advanced chronic liver disease in the HALT-C trial. Clin Gastroenterol Hepatol. 2010 Oct;8(10):877-83. doi: 10.1016/j.cgh.2010.03.025. Epub 2010 Apr 1. |
| 20211180 | Derived | Fontana RJ, Sanyal AJ, Ghany MG, Lee WM, Reid AE, Naishadham D, Everson GT, Kahn JA, Di Bisceglie AM, Szabo G, Morgan TR, Everhart JE; HALT-C Trial Group. Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C. Gastroenterology. 2010 Jun;138(7):2321-31, 2331.e1-2. doi: 10.1053/j.gastro.2010.02.058. Epub 2010 Mar 6. |
| 20070284 | Derived | Snow KK, Bonkovsky HL, Fontana RJ, Kim HY, Sterling RK, Di Bisceglie AM, Morgan TR, Dienstag JL, Ghany MG; HALT-C Trial Group. Changes in quality of life and sexual health are associated with low-dose peginterferon therapy and disease progression in patients with chronic hepatitis C. Aliment Pharmacol Ther. 2010 Apr;31(7):719-34. doi: 10.1111/j.1365-2036.2010.04235.x. Epub 2010 Jan 12. |
| 19852963 | Derived | Lok AS, Sterling RK, Everhart JE, Wright EC, Hoefs JC, Di Bisceglie AM, Morgan TR, Kim HY, Lee WM, Bonkovsky HL, Dienstag JL; HALT-C Trial Group. Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma. Gastroenterology. 2010 Feb;138(2):493-502. doi: 10.1053/j.gastro.2009.10.031. Epub 2009 Oct 20. |
| 19766643 | Derived | Ghany MG, Lok AS, Everhart JE, Everson GT, Lee WM, Curto TM, Wright EC, Stoddard AM, Sterling RK, Di Bisceglie AM, Bonkovsky HL, Morishima C, Morgan TR, Dienstag JL; HALT-C Trial Group. Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology. 2010 Jan;138(1):136-46. doi: 10.1053/j.gastro.2009.09.007. Epub 2009 Sep 18. |
| 19747918 | Derived | Shiffman ML, Morishima C, Dienstag JL, Lindsay KL, Hoefs JC, Lee WM, Wright EC, Naishadham D, Everson GT, Lok AS, Di Bisceglie AM, Bonkovsky HL, Ghany MG; HALT-C Trial Group. Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial. Gastroenterology. 2009 Dec;137(6):1986-94. doi: 10.1053/j.gastro.2009.08.067. Epub 2009 Sep 10. |
| 19676128 | Derived | Freedman ND, Everhart JE, Lindsay KL, Ghany MG, Curto TM, Shiffman ML, Lee WM, Lok AS, Di Bisceglie AM, Bonkovsky HL, Hoefs JC, Dienstag JL, Morishima C, Abnet CC, Sinha R; HALT-C Trial Group. Coffee intake is associated with lower rates of liver disease progression in chronic hepatitis C. Hepatology. 2009 Nov;50(5):1360-9. doi: 10.1002/hep.23162. |
| 19445938 | Derived | Everhart JE, Lok AS, Kim HY, Morgan TR, Lindsay KL, Chung RT, Bonkovsky HL, Ghany MG; HALT-C Trial Group. Weight-related effects on disease progression in the hepatitis C antiviral long-term treatment against cirrhosis trial. Gastroenterology. 2009 Aug;137(2):549-57. doi: 10.1053/j.gastro.2009.05.007. Epub 2009 May 13. |
| 19291787 | Derived | Lok AS, Everhart JE, Chung RT, Kim HY, Everson GT, Hoefs JC, Greenson JK, Sterling RK, Lindsay KL, Lee WM, Di Bisceglie AM, Bonkovsky HL, Ghany MG, Morishima C; HALT-C Trial Group. Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial. Hepatology. 2009 Jun;49(6):1828-37. doi: 10.1002/hep.22865. |
| 18848939 | Derived | Lok AS, Seeff LB, Morgan TR, di Bisceglie AM, Sterling RK, Curto TM, Everson GT, Lindsay KL, Lee WM, Bonkovsky HL, Dienstag JL, Ghany MG, Morishima C, Goodman ZD; HALT-C Trial Group. Incidence of hepatocellular carcinoma and associated risk factors in hepatitis C-related advanced liver disease. Gastroenterology. 2009 Jan;136(1):138-48. doi: 10.1053/j.gastro.2008.09.014. Epub 2008 Sep 18. |
| 18237873 | Derived | Lindsay KL, Morishima C, Wright EC, Dienstag JL, Shiffman ML, Everson GT, Lok AS, Bonkovsky HL, Lee WM, Morgan TR, Ghany MG; HALT-C Trial. Blunted cytopenias and weight loss: new correlates of virologic null response to re-treatment of chronic hepatitis C. Clin Gastroenterol Hepatol. 2008 Feb;6(2):234-41. doi: 10.1016/j.cgh.2007.11.020. |
| COMPLETED |
|
| NOT COMPLETED |
|
|
Not provided
| ID | Title | Description |
|---|---|---|
| BG000 | Peginterferon Alfa-2a 90 mcg/Week | Treatment with Peginterferon alfa-2a 90 mcg administered once weekly for an additional 42 months |
| BG001 | Standard of Care Followup | Stop any peginterferon alfa-2a/ribavirin therapy and followed prospectively for an additional 42 months without treatment |
| BG002 | Total | Total of all reporting groups |
| Units | Counts |
|---|---|
| Participants |
|
| Title | Description | Population Description | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Denominator Units Selected | Denominators | Classes | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age, Categorical | Count of Participants | Participants |
| ||||||||||||||||||
| Age, Continuous | Mean | Standard Deviation | years |
| |||||||||||||||||
| Sex: Female, Male | Count of Participants | Participants |
| ||||||||||||||||||
| Region of Enrollment | Number | participants |
|
| Type | Title | Description | Population Description | Reporting Status | Anticipated Posting Date | Parameter Type | Dispersion Type | Unit of Measure | Calculate Percentage | Time Frame | Units Analyzed | Denominator Units Selected | Arm/Group Information | Denominators | Classes | Analyses | |||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Primary | Progression of Liver Disease as Indicated by Death, Hepatic Decompensation, Hepatocellular Carcinoma, or for Patients With Noncirrhotic Fibrosis at Baseline, an Increase in the Ishak Hepatic Fibrosis Score of 2 or More Points | Progression of liver disease within 1400 days as indicated by death, hepatic decompensation (variceal hemorrhage; ascites; spontaneous bacterial peritonitis; hepatic encephalopathy), hepatocellular carcinoma, a Child-Turcotte-Pugh (CTP) score of 7 or more on two consecutive study visits (score range 5-15, higher score indicates greater decompensation), or for patients with noncirrhotic fibrosis at baseline, an increase in Ishak hepatic fibrosis score (range 0-6, higher score indicates greater fibrosis) of at least 2 points by assessment of a liver-biopsy specimen obtained during the study | Posted | Count of Participants | Participants | 1400 days (3.85 years) post randomization |
|
|
| ||||||||||||||||||||||||||||||
| Primary | Increase in Ishak Fibrosis Score by 2 Points or More at 2 or 4 Year Biopsies | For patients with noncirrhotic fibrosis at baseline, an increase in Ishak hepatic fibrosis score (range 0-6, higher score indicates greater fibrosis) of at least 2 points by assessment of a liver-biopsy specimen obtained during the study (collected at Year 2 and Year 4 biopsies, 1.5 and 3.5 years after randomization) | Patients with Ishak fibrosis score <5 at baseline and at least one follow-up biopsy | Posted | Count of Participants | Participants | 1400 days (3.85 years) post randomization |
|
| ||||||||||||||||||||||||||||||
| Primary | Death From Any Cause | Posted | Count of Participants | Participants | 1400 days (3.85 years) post randomization |
|
| ||||||||||||||||||||||||||||||||
| Primary | Development of Hepatocellular Carcinoma (HCC) | A diagnosis of development of hepatocellular carcinoma (HCC) was based on either
| Posted | Count of Participants | Participants | 1400 days (3.85 years) post randomization |
|
| |||||||||||||||||||||||||||||||
| Primary | Child-Turcotte-Pugh (CTP) Score of 7 or Higher at Two Consecutive Study Visits | Child-Turcotte-Pugh (CTP) score of 7 or more on two consecutive study visits (score range 5-15, higher score indicates greater hepatic decompensation) | Posted | Count of Participants | Participants | 1400 days (3.85 years) post randomization |
|
| |||||||||||||||||||||||||||||||
| Primary | Variceal Hemorrhage | A gastrointestinal hemorrhage which is believed by the investigator to be due to bleeding esophageal or gastric varices. In general, an endoscopy will have been performed and will have revealed either direct evidence of variceal bleeding (bleeding varix, red wale sign) or historical evidence for significant upper gastro-intestinal bleeding plus upper endoscopy revealing moderate varices and no other site of bleeding is identified | Posted | Count of Participants | Participants | 1400 days (3.85 years) post randomization |
|
| |||||||||||||||||||||||||||||||
| Primary | Ascites | Any abdominal fluid which is:
| Posted | Count of Participants | Participants | 1400 days (3.85 years) post randomization |
|
| |||||||||||||||||||||||||||||||
| Primary | Spontaneous Bacterial Peritonitis | Any episode of spontaneous ascitic infection diagnosed on the basis of elevated neutrophil count (> 250/ml) in paracentesis fluid or positive bacterial cultures and clinical diagnosis in the absence of white blood cell (WBC) availability. | Posted | Count of Participants | Participants | 1400 days (3.85 years) post randomization |
|
| |||||||||||||||||||||||||||||||
| Primary | Hepatic Encephalopathy | Any mental status alteration which is deemed by the investigator to be due to portosystemic encephalopathy, whether occurring during a provoked episode (GI bleeding, diuretics, usual sedative doses), or spontaneously (without apparent cause). | Posted | Count of Participants | Participants | 1400 days (3.85 years) post randomization |
|
| |||||||||||||||||||||||||||||||
| Secondary | Serious Adverse Events | A serious adverse event (SAE) is an untoward medical occurrence that results in any of the following:
Trial outcomes (except death) were not considered serious adverse events. | Posted | Count of Participants | Participants | 1400 days (3.85 years) post randomization |
|
| |||||||||||||||||||||||||||||||
| Secondary | Changes in Fibrosis From Baseline at Year 2 or Year 4 Biopsy. | Change in Ishak hepatic fibrosis score (range 0-6, higher score indicates greater fibrosis) by assessment of a liver-biopsy specimen obtained during the study (collected at baseline, Year 2 and Year 4 biopsies, 1.5 and 3.5 years after randomization) | Numbers of participants at 1.5 and 3.5 years are the number with biopsies at those time points | Posted | Mean | Standard Deviation | units on a scale | 1400 days (3.85 years) post randomization |
|
| |||||||||||||||||||||||||||||
| Secondary | Presumed Hepatocellular Carcinoma (HCC) | Presumed HCC was considered when histology was not available and alpha-fetoprotein (AFP) is <1000 ng/ml, if:
| Posted | Count of Participants | Participants | 1400 days (3.85 years) post randomization |
|
| |||||||||||||||||||||||||||||||
| Secondary | SF-36 Vitality Summary Score | Change from baseline to years 0.5, 1.5, 2.5, and 3.5 in Short Form Health Survey (SF-36) Vitality summary score. The SF-36 Vitality summary score is the sum of 4 individual scores. It is scaled from 0 to 100 with a score of 0 equivalent to maximum disability and a score of 100 equivalent to no disability. A negative value indicates a decrease in quality of life from baseline. | At each visit the analysis population is the number who completed the questionaire | Posted | Mean | Standard Deviation | units on a scale | 0.5, 1.5, 2.5, and 3.5 years after randomization |
|
| |||||||||||||||||||||||||||||
| Secondary | SF-36 Physical Function Summary Score | Change from baseline to years 0.5, 1.5, 2.5, and 3.5 in Short Form Health Survey (SF-36) Physical Function summary score. The SF-36 Physical Function summary score is the sum of 10 individual scores. It is scaled from 0 to 100 with a score of 0 equivalent to maximum disability and a score of 100 equivalent to no disability. A negative value indicates a decrease in quality of life from baseline. | At each visit the analysis population is the number who completed the questionaire | Posted | Mean | Standard Deviation | units on a scale | 0.5, 1.5, 2.5, and 3.5 years after randomization |
|
| |||||||||||||||||||||||||||||
| Secondary | SF-36 Mental Health Summary Score | Change from baseline to years 0.5, 1.5, 2.5, and 3.5 in Short Form Health Survey (SF-36) Mental Health summary score. The SF-36 Mental Health summary score is the sum of 5 individual scores. It is scaled from 0 to 100 with a score of 0 equivalent to maximum disability and a score of 100 equivalent to no disability. A negative value indicates a decrease in quality of life from baseline. | At each visit the analysis population is the number who completed the questionaire | Posted | Mean | Standard Deviation | units on a scale | 0.5, 1.5, 2.5, and 3.5 years after randomization |
|
|
Within 1400 days (3.83 years) after randomization
In the treatment group, 3991 adverse events occurred among 486 patients, as compared with 3129 adverse events among 492 patients in the control group; 330 patients had at least one serious adverse event.
Not provided
| ID | Title | Description | Deaths (Affected) | Deaths (At Risk) | Serious Events (Affected) | Serious Events (At Risk) | Other Events (Affected) | Other Events (At Risk) |
|---|---|---|---|---|---|---|---|---|
| EG000 | Peginterferon Alfa-2a 90 mcg/Week | Treatment with Peginterferon alfa-2a 90 mcg administered once weekly for an additional 42 months | 175 | 517 | 486 | 517 | ||
| EG001 | Standard of Care Followup | Stop any peginterferon alfa-2a/ribavirin therapy and followed prospectively for an additional 42 months without treatment | 155 | 533 | 492 | 533 |
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anemia | Blood and lymphatic system disorders | Systematic Assessment |
| ||
| Thrombocytopenia or pancytopenia | Blood and lymphatic system disorders | Systematic Assessment |
| ||
| Atherosclerotic disease | Cardiac disorders | Systematic Assessment |
| ||
| Arrhythmia | Cardiac disorders | Systematic Assessment |
| ||
| Other cardiovascular or circulatory event | Cardiac disorders | Systematic Assessment |
| ||
| Nonvariceal gastrointestinal bleeding | Gastrointestinal disorders | Systematic Assessment |
| ||
| Hernia or intestinal obstruction | Gastrointestinal disorders | Systematic Assessment |
| ||
| Other digestive system event | Gastrointestinal disorders | Systematic Assessment |
| ||
| Electrolyte, mineral, or water imbalance | Endocrine disorders | Systematic Assessment |
| ||
| Diabetes and its complications | Endocrine disorders | Systematic Assessment |
| ||
| Thyroid disease | Endocrine disorders | Systematic Assessment |
| ||
| Renal or urinary diseases | Renal and urinary disorders | Systematic Assessment |
| ||
| Gynecologic, menstrual, or sexual disorders | Reproductive system and breast disorders | Systematic Assessment |
| ||
| Gallbladder disease | Hepatobiliary disorders | Systematic Assessment |
| ||
| Other pancreatic or biliary disorders | Hepatobiliary disorders | Systematic Assessment |
| ||
| Liver-disease events other than primary or secondary outcomes | Hepatobiliary disorders | Systematic Assessment | Liver-disease events not related to death or other study-related clinical primary or secondary outcomes of the trial |
| |
| Mucocutaneous infection and infectious diseases | Infections and infestations | Systematic Assessment |
| ||
| Respiratory tract infections and infectious diseases | Infections and infestations | Systematic Assessment |
| ||
| Systemic infections and infectious diseases | Infections and infestations | Systematic Assessment |
| ||
| Other infections and infectious diseases | Infections and infestations | Systematic Assessment |
| ||
| Injury | Injury, poisoning and procedural complications | Systematic Assessment |
| ||
| Drug reaction | Injury, poisoning and procedural complications | Systematic Assessment |
| ||
| Liver-biopsy complication | Injury, poisoning and procedural complications | Systematic Assessment |
| ||
| Musculoskelatal surgery | Musculoskeletal and connective tissue disorders | Systematic Assessment |
| ||
| Arthritis or back pain | Musculoskeletal and connective tissue disorders | Systematic Assessment |
| ||
| Malignant neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Systematic Assessment |
| ||
| Benign neoplasm | Neoplasms benign, malignant and unspecified (incl cysts and polyps) | Systematic Assessment |
| ||
| Cerebral aneurysm, infarct, or stroke | Nervous system disorders | Systematic Assessment |
| ||
| Other neurologic event | Nervous system disorders | Systematic Assessment |
| ||
| Affective disorders or delirium | Psychiatric disorders | Systematic Assessment |
| ||
| Suicidal ideation or attempt | Psychiatric disorders | Systematic Assessment |
| ||
| Substance abuse | Psychiatric disorders | Systematic Assessment |
| ||
| Respiratory disorders | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
| ||
| Benign skin and nail disorders | Skin and subcutaneous tissue disorders | Systematic Assessment |
| ||
| Cardiovascular signs or symptoms | General disorders | Systematic Assessment | These clinical signs and symptoms are not associated with a specific diagnosis but are still classified as a serious adverse event. |
| |
| Hepatobiliary signs or symptoms | General disorders | Systematic Assessment | These clinical signs and symptoms are not associated with a specific diagnosis but are still classified as a serious adverse event. |
| |
| Neurologic signs or symptoms | General disorders | Systematic Assessment | These clinical signs and symptoms are not associated with a specific diagnosis but are still classified as a serious adverse event. |
| |
| Digestive signs or symptoms | General disorders | Systematic Assessment | These clinical signs and symptoms are not associated with a specific diagnosis but are still classified as a serious adverse event. |
| |
| Other general signs or symptoms | General disorders | Systematic Assessment | These clinical signs and symptoms are not associated with a specific diagnosis but are still classified as a serious adverse event. |
|
| Term | Organ System | Source Vocabulary | Assessment Type | Notes | Statistical Information |
|---|---|---|---|---|---|
| Anemia | Blood and lymphatic system disorders | Systematic Assessment |
| ||
| Hypertension | Cardiac disorders | Systematic Assessment |
| ||
| Diabetes | Endocrine disorders | Systematic Assessment |
| ||
| Sexual dysfunction, impotence | Reproductive system and breast disorders | Systematic Assessment |
| ||
| Cystitis, bladder infection | Infections and infestations | Systematic Assessment |
| ||
| Pharyngitis | Infections and infestations | Systematic Assessment |
| ||
| Pneumonia | Immune system disorders | Systematic Assessment |
| ||
| Sinusitis | Infections and infestations | Systematic Assessment |
| ||
| Upper respiratory infection | Infections and infestations | Systematic Assessment |
| ||
| Arthralgia | Musculoskeletal and connective tissue disorders | Systematic Assessment |
| ||
| Bursitis, tendonitis, enthesopathies | Musculoskeletal and connective tissue disorders | Systematic Assessment |
| ||
| Limb pain | Musculoskeletal and connective tissue disorders | Systematic Assessment |
| ||
| Muscle spasm | Musculoskeletal and connective tissue disorders | Systematic Assessment |
| ||
| Muscle/back aches or pain | Musculoskeletal and connective tissue disorders | Systematic Assessment |
| ||
| Anxiety | Psychiatric disorders | Systematic Assessment |
| ||
| Depression | Psychiatric disorders | Systematic Assessment |
| ||
| Bronchitis | Respiratory, thoracic and mediastinal disorders | Systematic Assessment |
| ||
| Chest pain | General disorders | Systematic Assessment |
| ||
| Diarrhea, loose stool | General disorders | Systematic Assessment |
| ||
| Nausea | General disorders | Systematic Assessment |
| ||
| Abdominal pain | Hepatobiliary disorders | Systematic Assessment |
| ||
| Dizziness, vertigo, light-headedness | General disorders | Systematic Assessment |
| ||
| Headache | General disorders | Systematic Assessment |
| ||
| Insomnia, sleep disturbance | General disorders | Systematic Assessment |
| ||
| Memory loss, confusion | General disorders | Systematic Assessment |
| ||
| Tingling, numbness | General disorders | Systematic Assessment |
| ||
| Nervousness, irritability | General disorders | Systematic Assessment |
| ||
| Nonproductive cough | General disorders | Systematic Assessment |
| ||
| Dyspnea | General disorders | Systematic Assessment |
| ||
| Rash | General disorders | Systematic Assessment |
| ||
| Body aches, chills, fever | General disorders | Systematic Assessment |
| ||
| Fatigue, malaise, weakness | General disorders | Systematic Assessment |
| ||
| Localized edema | General disorders | Systematic Assessment |
| ||
| Pruritis | Skin and subcutaneous tissue disorders | Systematic Assessment |
|
Not provided
Not provided
| Title | Organization | Phone | Extension | |
|---|---|---|---|---|
| James E. Everhart, MD, MPH, Project Officer | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | 301-594-8878 | EverhartJ@extra.niddk.nih.gov |
| ID | Term |
|---|---|
| D019698 | Hepatitis C, Chronic |
| D008103 | Liver Cirrhosis |
| D008107 | Liver Diseases |
| D006526 | Hepatitis C |
| D005355 | Fibrosis |
| ID | Term |
|---|---|
| D000086982 | Blood-Borne Infections |
| D003141 | Communicable Diseases |
| D007239 | Infections |
| D006525 | Hepatitis, Viral, Human |
| D014777 | Virus Diseases |
| D018178 | Flaviviridae Infections |
| D012327 | RNA Virus Infections |
| D006521 | Hepatitis, Chronic |
| D006505 | Hepatitis |
| D004066 | Digestive System Diseases |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided
| ID | Term |
|---|---|
| C100416 | peginterferon alfa-2a |
| D012254 | Ribavirin |
| ID | Term |
|---|---|
| D012263 | Ribonucleosides |
| D009705 | Nucleosides |
| D009706 | Nucleic Acids, Nucleotides, and Nucleosides |
Not provided
Not provided
| >=65 years |
|
| Male |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|